Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myriad Genetics, Inc. (MYGN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1723)	11/16/2005 7:15:45 PM
From: John McCarthy	Respond to of 2355

Hi Tuck ... <<<<< Where's the beef? <<<<< When it comes to understanding trial results I run to SI and get the facts here. Otherwise I'd be lost .... so hopefully they will release more data and it will get sorted out here. This may make you wince but what the heck .... When I read the press release the first thing I thought of was MCI (Mild Cognitive Impairment) and not AD. It may sound foolish and in fact may be foolish .... but its a place everyone is trying to get to (Aricept and Alzemed (?)) to name two and thats what came to mind when I read their press release. On the AD Info Sheet they write .... <<<<<<<<< Complaints of memory loss are extremely common and probably occur in everybody at some point during their life, particularly as they get older. It is estimated that 15 per cent of the population may be experiencing MCI. <<<<<<<<< so thats alot of bodies. regards, John

To: tuck who wrote (1723)	11/28/2005 1:25:42 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 2355

I had never looked at this board before, but in preparing an AD review, I was looking for alternative points of view, given what I thought was a very strange clinical program for Flurizan. So this is where Rick H has been. Anyways, it was useful and entertaining going back through a few months of posts, so here are a couple of thoughts about the Flurizan program: 1) 86 patients enrolled in the follow-on, they had to be getting drug in the main trial to be eligible. Only 41 completed the six months of followon reported, which seems strikingly low to me. 23 were in the 800mg group that had this 'miraculous' improvement in ADAS-cog. Looks like the nonresponders gave up and quit, so this sample is highly skewed. I do not take this as indicating some rescue of the Alzheimer's 'penumbra' of cells on the edge. 2) Myriad doesnt appear to have taken its own numbers seriously either. If there were some cell resurrection/recovery process going on in the 12-18 month area, in contrast to the converging lines of 9-12 months, you'd think they'd like to use that in Phase III. Instead, it's a 12 month study. In contrast to the 18 month timeframes being used in Phase III by Neurochem and Voyager. Based on very little review, Myriad looks like an interesting predictive medicine company. Harry NeuroInvestment